ESMO-CSCO-JSMO-KACO Joint Symposium



Asian Advanced Gastric Cancer

Hyun Cheol Chung, M.D., Ph.D. Yonsei Cancer Center Yonsei University College of Medicine Seoul, Korea



Disclosure

- Research fund, material: Lilly, MSD, GSK
- Advisor: MSD, Lilly, Celltrion, Taiho, Quintiles
- Speaker: Merck-Serono



I. Incidence


II. Tumor biology and clinical characteristics

III. Host characteristics

IV. Treatment pattern



I-1. Incidence and stage distribution (tumor burden)




SINGAPORE

I-2. Current treatment outcomes

■ '93-'95 ■ '96-'00 ■ '01-'05 ■ '07-'11

o the SEER web site, April 2014, 3) Canadian Cancer Society, Statistics Canada and Provincial/Territorial Cancer

Monitoring of Cancer Incidence in Japan - Survival 2003-2005 report 2013, 5) Kyu-Won Jung, Young-Joo Won et



1) Major cancer sites selected based on 2011 crude rates * difference in the cancer survival probability between '93~'95 and '07~'11, 2) Howlader N, Noone AM, et alSEER Cancer Statistics Review, 1975-2011, National Cancer

Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, hased Registry. Cancer Statistics 2014 4, Gener for Cancer Control a al. Cancer Designed Statistics 2014 4, Gener for Cancer Control a



II-1. Histological difference

TABLE 3. Patholog	gical Cha	racteristi	CS				Korea/Japan	USA
	Country				TT	TT	-	
		rea 1646	United S N = 7			Upper	Undifferentiated, diffuse	More obese, male intestinal
Variable	No. Patients	%	No. Patients	%	Р	Lower	Older	Female (1:1)
Location of tumor					< 0.0001*	8		
GE junction	7	0.40%	131	18%		L OIS		
Upper	142	9%	146	21%		³⁵	3,667 tumour samples from 2	24 countries in TOGA trial
Middle	592	36%	189	27%		2 30 - 2 25 - 8 20 -	Line and the second sec	
Lower	886	54%	232	33%		8 20 -		
Whole	7	0.40%	13	2%		N 15 ·		
Unknown	12	1%	_			تُ 10-		
Differentiation					0.07*	ů La		
Differentiated	770	47%	361	51%			- 001	
Undifferentiated	857	52%	342	48%		Gastric cancer	∎GEJ cancer	
Unknown	19	1%	8	1%		Gastric cancer		
Lauren classification					< 0.0001*	0 40 -		
Diffuse	623	38%	203	29%		20 •		
Intestinal	729	44%	419	59%				e le le le le le la
Mixed	257	16%	79	11%		with which which	rende and the same are been and a same and a same	, where the state was a state and the state
N/A or unknown	37	2%	10	1%		Sr. De. X.	, Co. ¹ 2, Co. 4, 6, 6, 4,	Cost. Cult

25 114). 640-646, 2 Uggehrheim &

SINGAPORE


Strong VEINSOAD KYet a

2015

Oncol 2013:107:230, Shim HJ, Song KY et al. Ann Surg Oncol 2014:21:2332-2339

in all

II-2. Genome and TCGA subtype difference



* unpublished


III. Host characteristics


	Cou	ntry		
	Korea	United States	Р	
No. patients	1646	711		
Male	1096	425	0.002*	
Female	550	286	0.002*	
Median age (yr) (range)	59 (18–91)	69 (22–96)	$< 0.0001^{\dagger}$	Affects chemotherapy
BMI (kg/m ²) [‡] median	22.6 (13.7-35.9)	25.4 (14.1-47.6)	$< 0.0001^{\dagger}$	outcome!
(range)				
Race				
Caucasian		538 (76%)		
Black		45 (6%)		
Asian	1646 (100%)	74 (10%)		
Hispanic	_	53 (7%)		
Other	_	1 (0.1%)		
Family history			< 0.0001*	
Yes	87 (5%)	92 (13%)		Genetic family history vs
No	1559 (95%)	579 (81%)		Environmental family history
Unknown		40 (6%)		





Surg Oncol 2014:21:2332-2339


III-1. Immune & micro-environmental factors












III-2. Immune checkpoint inhibitors



2015

	Total N = 39	Non-Asian n = 20	Asian n = 19			
ORR, ^a % (95% CI)	30.8 (17.0-47.6)	30.0 (11.9-54.3)	31.6 (12.6-56.6)			
Best overall response, n (%)						
Complete response	0	0	0			
Partial response	12 (30.8)	6 (30.0)	6 (31.6)			
Stable disease	5 (12.8)	1 (5.0)	4 (21.1)			
Progressive disease	21 (53.8)	12 (60.0)	9 (47.4)			
Not evaluable	1 (2.6)	1 (5.0)	0			

Avelumab **Durvalumab** PR (N=3) 8D (N=6) PD (N=6) NE (N=1) 60 50 50 20 10 2L group → on-going -10 -20 -30 -40 70 -60 -50 -30 -30 -10 --10 --20 --30 --40 --60 --60 --70 --60 --70 --CR (N=1) PR (N=3) SD (N=26 PD (N=14 NE (N=1) SwM group 18-21 DECEMBER SINGAPORE SINGAPORE

- Screening program (early diagnosis, low tumor burden, long-term survival): EGC 68% at 2004 (Japan), 46-67% (Korea)
- **Palliative chemotherapy**: Doublet vs triplet, various regimens, lines of treatment
- **Supportive care**: GI-GU-Biliary stent, draining pigtail, palliative radiotherapy, hyperalimentation, pain control, anti-emetics



IV-1. Trends in palliative chemotherapy


(5-FU analogue + platinum) (FP/XP/SP/FOLFOX/CapOX/SOX) Adding trastuzumab in Her-2 + patients

Asia


North America (5-FU/cisplatin, DCF)


Europe (ECF/EOX)





IV-2. Regional difference in OS





DASIA 18-21 DECEMBER SINGAPORE

SINGAPORE

2015

IV-3. Culture and policy-related issues

- Herbal medicine
- Drug availability and reimbursement
- Cultural uniqueness:
 - continued chemotherapy with good PS: 4th, 5th line,
 - clinical trials
- Different attitude for hospice care (short survival after PD)







Figure 1. Stepwise improvements in efficacy of chemotherapy for early-stage breast cancer.⁶




Longer PFS/Better PS→ Next regimen (Relay Race)

18-21 DECEMBER



Summary

	EAST	WEST			
Incidence/prevalence/Age	High/50s	Low/60s			
Tumor burden/stage	Low	High			
Location	distal	proximal			
Histology	diffuse	intestinal			
TCGA EBV MSI GS CIN Immune	4-7% 5-11% 39% 53% Treg	9% 22% 20% 50% T cell pathway			
	EAST	WEST			
Localized (National screen)	Better endoscopist, radiologist				
Regional (D2)	Better surgeon				
Systemic		Better drug reimburse			
Survival	Better in stage II-IV	Similar in stage I			
SINGAPORE ENVIO					



Asian cancer: $\geq 3^{rd}$ line treatment(12~15 months)Non-Asian cancer: $\leq 2^{nd}$ line treatment(8~10 months)





Acknowledgement

Gastric Cancer Center

Medical Oncology: Hyun Cheol Chung, Hyo Song Kim, Min Kyu Jung, Seung Hoon Beum Surgical Onoclogy: Sung Hoon Noh, Woo Jin Hyung, Jae Ho Jeong, Hyung Il Kim Gastroenterology: Yong Chan Lee, Sang Gil Lee, Hyun Soo Jung Pathology Hyun Ki Kim, Radiology: Jun Seok Lim

"Gastric cancer is heterogeneous, but a globally manageable disease."



ESMO-CSCO-JSMO-KACO **Joint Symposium**





